Pharma channel feed – Endpoints News

Pharma channel feed

Not your mom’s probiotic: GV-backed Evelo teams up with Mayo Clinic on microbiome drugs

8 years ago

Ultragenyx lands first FDA OK, with another on the horizon in shift to commercial ops

8 years ago

Alkermes touts equal efficacy of monthly Vivitrol against daily Suboxone

8 years ago

Genentech inks $650M deal with protein degradation pioneer Arvinas

8 years ago

AstraZeneca’s respiratory group scores FDA OK for a blockbuster severe asthma drug

8 years ago

Mirati bails on lead drug, shifts focus to I/O program

8 years ago

Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs

8 years ago

Pfizer CEO Read hands off drug development responsibilities to his hand picked successor

8 years ago

Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market

8 years ago

Ex-Eli Lilly exec Azar lands HHS nomination as Trump champions lower drug prices

8 years ago

J&J antes $50M to get Zymeworks' 6th big bispecifics alliance underway, with $6B in total milestones on the table

8 years ago

Sangamo joins biotech migration to Oyster Point with new HQ

8 years ago

Aiming for more copycats of each branded drug, FDA expands generic drug priority reviews

8 years ago

Dynavax caps a long-running regulatory saga with an FDA OK for hep B vaccine Heplisav

8 years ago

Gottlieb: 'End the shenanigans' on slow-playing REMS to delay generic drug competition

8 years ago

Watch out Merck: Heron snagged FDA approval on Emend competitor

8 years ago

Inching closer to blockbuster status, Seattle Genetics gets fourth FDA win for Adcetris

8 years ago

Merck wins FDA OK for new CMV drug Prevymis, triggering a $122M payday for AiCuris

8 years ago

Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal

8 years ago

Surprise: Did Otonomy bring its lead ear drug back from the dead?

8 years ago

Kerrisdale’s Sahm Adrangi leads a brutal new biotech short attack as trial results loom

8 years ago

Who are the top 10 players that dominate the cancer drug market? And who's growing fastest?

8 years ago

An early SITC loser: Five Prime shares crushed as analysts fret over a snapshot on lead drug data

8 years ago

How much is your vision worth? Spark CEO Jeff Marrazzo has a price in mind

8 years ago

First page Previous page 309 310 311312313 314 315 Next page Last page